ReviewCNS neuroscience & therapeutics2010
Pregabalin in the treatment of alcohol and benzodiazepines dependence.
Review in CNS neuroscience & therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02884908 (Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Exploratory study of heart rate variability among participants with opioid use disorder inducted on gabapentin versus placebo during outpatient buprenorphine-assisted transition to injection naltrexone.Experimental and clinical psychopharmacology · 2025Trial
- Effects of pregabalin in patients with hypnotic-dependent insomnia.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2014Trial
- Pregabalin Dependence and Management in a 55-Year-Old Female with Chronic Low Back Pain.Cureus · 2023Article
- Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance.Frontiers in psychiatry · 2021Article
- Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France.British journal of clinical pharmacology · 2019Observational
- Pharmacotherapy for Co-Occurring Alcohol Use Disorder and Post-Traumatic Stress Disorder: Targeting the Opioidergic, Noradrenergic, Serotonergic, and GABAergic/Glutamatergic Systems.Alcohol research : current reviews · 2018Review
- Gabapentinoids in penitentiaries: An abuse and addiction research.Turkish journal of physical medicine and rehabilitation · 2017Article
- Pregabalin for the Treatment of Drug and Alcohol Withdrawal Symptoms: A Comprehensive Review.CNS drugs · 2016Review
- Pharmacological Approaches for Treatment-resistant Bipolar Disorder.Current neuropharmacology · 2015Review
- Factors associated with pregabalin dispensing at higher than the approved maximum dose.European journal of clinical pharmacology · 2014Article
- Pharmacological strategies for detoxification.British journal of clinical pharmacology · 2014Review
- Pregabalin- and topiramate-mediated regulation of cognitive and motor impulsivity in DBA/2 mice.British journal of pharmacology · 2012Article
- Pregabalin in the treatment of refractory bipolar disorders.CNS neuroscience & therapeutics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We review all available studies on the use of the newer anticonvulsant drug pregabalin (PGB) in the treatment of both alcohol dependence (AD) and benzodiazepine dependence (BD). In AD, the available evidence includes one open-label and one double-blind randomized studies, whereas in BD, only a few case reports and one open-label study are as yet available. In both conditions, PGB was found efficacious with significant improvement in withdrawal symptoms at the dosage ranges of 150-450 mg/day (AD) and 225-900 mg/day (BD). Moreover, its side effects were mild and transient. Despite the limited quality of the studies design, their findings suggest that PGB might constitute a novel efficacious and safe option in the treatment of both AD and BD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.